A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Macitentan (Primary) ; Rosuvastatin
- Indications Congenital heart defects; Eisenmenger complex; Heart failure; Portal hypertension; Pulmonary hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 18 Dec 2017 Status changed from active, no longer recruiting to completed.
- 05 Dec 2017 New trial record